Remove Economics Remove Pharmaceutical Remove Valuation
article thumbnail

Factors impacting Perpetual Growth Rate in a DCF

Wizenius

Valuation is a complex art that requires a deep understanding of financial modeling and various influencing factors. Below are few factors that shape growth rate assumptions and present real-world examples from different geographies to shed light on the art of valuation. Take your career to new heights in the dynamic world of finance.

DCF 52
article thumbnail

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

company to hit a $1 trillion valuation , it directly benefited shareholders. Proponents argue that by fulfilling this responsibility, firms indirectly benefit society by driving economic growth and innovation. Comparing and Contrasting Both shareholders and stakeholders play crucial roles, but their focus and perspectives often differ.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40
article thumbnail

The SaaS Prescription: Healthcare Trends and M&A Insights

Software Equity Group

In 2022 and 2023, a time when M&A transactions in many industries declined due to economic conditions, healthcare M&A deals increased considerably. Thus, these realities are also driving a surge of M&A activity in the healthcare SaaS arena. Click here to fill out our assessment form.

article thumbnail

The SaaS Prescription: Healthcare Trends and M&A Insights

Software Equity Group

In 2022 and 2023, a time when M&A transactions in many industries declined due to economic conditions, healthcare M&A deals increased considerably. Thus, these realities are also driving a surge of M&A activity in the healthcare SaaS arena. Click here to fill out our assessment form.

article thumbnail

Cooley’s 2020 Life Sciences M&A Year in Review

Cooley M&A

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. While deal value was down for the year, deal volume was relatively stable (down only 2.0%

M&A 40
article thumbnail

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley M&A

In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 The Merger Agreement.